119 related articles for article (PubMed ID: 16011254)
21. Preparation of radiolabeled 9-cis- and all-trans-retinoids.
Tadikonda PK; DeLuca HF
Methods Enzymol; 1997; 282():108-17. PubMed ID: 9330281
[No Abstract] [Full Text] [Related]
22. Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase).
Schäfer A; Burstein ES; Olsson R
Bioorg Med Chem Lett; 2014 Apr; 24(8):1944-7. PubMed ID: 24666648
[TBL] [Abstract][Full Text] [Related]
23. Aza-retinoids as novel retinoid X receptor-specific agonists.
Farmer LJ; Marron KS; Canan Koch SS; Hwang CK; Kallel EA; Zhi L; Nadzan AM; Robertson DW; Bennani YL
Bioorg Med Chem Lett; 2006 May; 16(9):2352-6. PubMed ID: 16364638
[TBL] [Abstract][Full Text] [Related]
24. Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors.
Qi L; Guo Y; Zhang P; Cao X; Luan Y
Curr Drug Metab; 2016; 17(2):118-28. PubMed ID: 26806040
[TBL] [Abstract][Full Text] [Related]
25. Placental steroidogenesis in rats is independent of signaling pathways induced by retinoic acids.
Itoh K; Hiromori Y; Kato N; Yoshida I; Itoh N; Ike M; Nagase H; Tanaka K; Nakanishi T
Gen Comp Endocrinol; 2009 Sep; 163(3):285-91. PubMed ID: 19409899
[TBL] [Abstract][Full Text] [Related]
26. The effect of antagonists on the conformational exchange of the retinoid X receptor alpha ligand-binding domain.
Lu J; Dawson MI; Hu QY; Xia Z; Dambacher JD; Ye M; Zhang XK; Li E
Magn Reson Chem; 2009 Dec; 47(12):1071-80. PubMed ID: 19757405
[TBL] [Abstract][Full Text] [Related]
27. Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells.
Lee HY; Dawson MI; Walsh GL; Nesbitt JC; Eckert RL; Fuchs E; Hong WK; Lotan R; Kurie JM
Cell Growth Differ; 1996 Aug; 7(8):997-1004. PubMed ID: 8853895
[TBL] [Abstract][Full Text] [Related]
28. The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation
Gaunt CM; Rainbow DB; Mackenzie RJ; Jarvis LB; Mousa HS; Cunniffe N; Georgieva Z; Brown JW; Coles AJ; Jones JL
Front Immunol; 2021; 12():712241. PubMed ID: 34447379
[TBL] [Abstract][Full Text] [Related]
29. Novel silicon-containing analogues of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells.
Bauer JB; Lippert WP; Dörrich S; Tebbe D; Burschka C; Christie VB; Tams DM; Henderson AP; Murray BA; Marder TB; Przyborski SA; Tacke R
ChemMedChem; 2011 Aug; 6(8):1509-17. PubMed ID: 21726055
[TBL] [Abstract][Full Text] [Related]
30. Replacement of the hydrophobic part of 9-cis-retinoic acid with cyclic terpenoid moiety results in RXR-selective agonistic activity.
Okitsu T; Sato K; Iwatsuka K; Sawada N; Nakagawa K; Okano T; Yamada S; Kakuta H; Wada A
Bioorg Med Chem; 2011 May; 19(9):2939-49. PubMed ID: 21489804
[TBL] [Abstract][Full Text] [Related]
31. DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
Heitel P; Achenbach J; Moser D; Proschak E; Merk D
Bioorg Med Chem Lett; 2017 Mar; 27(5):1193-1198. PubMed ID: 28169169
[TBL] [Abstract][Full Text] [Related]
32. Antagonist-perturbation mechanism for activation function-2 fixed motifs: active conformation and docking mode of retinoid X receptor antagonists.
Tsuji M
J Comput Aided Mol Des; 2017 Jun; 31(6):577-585. PubMed ID: 28534193
[TBL] [Abstract][Full Text] [Related]
33. RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
Wang L; DeMarco SS; Peaks MS; Maiorana-Boutilier AL; Chen J; Crouch MJ; Shewchuk BM; Shaikh SR; Phillips CM; Bridges LC
Exp Dermatol; 2017 Nov; 26(11):1004-1011. PubMed ID: 28370539
[TBL] [Abstract][Full Text] [Related]
34. Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist effects on CRABP-II and RARbeta expression.
Hewson QC; Lovat PE; Pearson AD; Redfern CP
J Cell Biochem; 2002; 87(3):284-91. PubMed ID: 12397610
[TBL] [Abstract][Full Text] [Related]
35. Bexarotene: a promising anticancer agent.
Qu L; Tang X
Cancer Chemother Pharmacol; 2010 Jan; 65(2):201-5. PubMed ID: 19777233
[TBL] [Abstract][Full Text] [Related]
36. RXR agonists inhibit high glucose-induced upregulation of inflammation by suppressing activation of the NADPH oxidase-nuclear factor-κB pathway in human endothelial cells.
Ning RB; Zhu J; Chai DJ; Xu CS; Xie H; Lin XY; Zeng JZ; Lin JX
Genet Mol Res; 2013 Dec; 12(4):6692-707. PubMed ID: 24391011
[TBL] [Abstract][Full Text] [Related]
37. How retinoids regulate breast cancer cell proliferation and apoptosis.
Simeone AM; Tari AM
Cell Mol Life Sci; 2004 Jun; 61(12):1475-84. PubMed ID: 15197471
[TBL] [Abstract][Full Text] [Related]
38. Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids.
Hellemans K; Verbuyst P; Quartier E; Schuit F; Rombouts K; Chandraratna RA; Schuppan D; Geerts A
Hepatology; 2004 Jan; 39(1):97-108. PubMed ID: 14752828
[TBL] [Abstract][Full Text] [Related]
39. Retinoid X receptor ligands: a patent review (2007 - 2013).
Yamada S; Kakuta H
Expert Opin Ther Pat; 2014 Apr; 24(4):443-52. PubMed ID: 24456080
[TBL] [Abstract][Full Text] [Related]
40. Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles.
Pérez-Rodríguez S; Ortiz MA; Pereira R; Rodríguez-Barrios F; de Lera AR; Piedrafita FJ
Eur J Med Chem; 2009 Jun; 44(6):2434-46. PubMed ID: 19216008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
